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Abstract 
BACKGROUND: Mother’s mental state during pregnancy is of substantial importance for the mother, but also for 
the infant and his/her future growth and development. Depressive maternal disorders during pregnancy have a 
significant influence on the development of the baby during pregnancy as well as on the future development and 
mother-baby relation, the breastfeeding process and care for the baby. 
AIM: This study aimed to determine the influence of SSRI antidepressant therapy and psychosocial and 
therapeutic interventions on depression during pregnancy. It was also our aim to determine the relation between 
severity of depression and sociodemographic characteristics. 
METHODS: The study included 40 women, with diagnosis F32 and F33 according to ICD 10, that is, with severe 
depressive disorder within depressive episodes or recurrent depressive disorder. Patients were evaluated at the 
beginning of the treatment and 3 months after antidepressant treatment. They were followed-up for two years. 
RESULTS: The results obtained have shown that a larger number of mothers treated with antidepressant 
medications, had normal childbirth with the unremarkable condition of both, the mother and the newborn baby.  
CONCLUSION: A well-combined treatment of maternal depression during pregnancy reduces the risk of 
postpartum depression, which is by itself a prerequisite for normal emotional and behavioural development of the 
child. 
 
 
 
 
 
 
Introduction 
 
The mental state of the mother during 
pregnancy is of substantial importance for the mother, 
but also for the newborn baby and his/her future 
development. 
Depressive maternal disorders during 
pregnancy have a significant influence on the 
development of the baby during pregnancy as well as 
on the future development and mother-baby relation, 
the breastfeeding process and care for the baby. 
It is estimated that in about 7% of women 
during pregnancy psychic disorders have been 
detected, and in ¾ of them, a severe depressive 
condition has been observed.  
Although it is considered that the percentage 
of women with depression during pregnancy is about 
18%, still there is no sufficient information for 
adequate diagnosing and treatment of depression 
during pregnancy. 
Patients who were screened during 
pregnancy and diagnosed with depression were 
significantly more likely to ask for an expert opinion 
and help earlier during the postpartum period than 
those who were not recognised [1].  
An estimated 1-6% of women suffer from 
major depression while 15-25% have a milder form of 
depression. Postnatal or postpartum depression is 
usually associated with depression during pregnancy, 
especially if it has not been properly treated. 
Antidepressant maternal treatment reduces 
the risk of relapse or disease exacerbation during 
pregnancy [2]. 
Over the last two decades, the use of SSRI 
antidepressant medications during pregnancy has 
increased and has been given to 2-8% of pregnant 
women [3]. 
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Nancy Melville in her study about the risk 
factors for suicide in women reported that 4% of 
women who died by suicide in Great Britain during the 
period 1997-2012 were in their perinatal period (a 
period that is a few weeks before delivery). The most 
common diagnoses in these women were depression, 
bipolar disorders and personality disorders [4] [5]. The 
most common symptoms included depressed mood, 
self-harm, suicidal ideas and hopelessness. It has to 
be emphasised that in one-fifth of these women 
depression was not recognised, that is, they were not 
examined during their last month of pregnancy. 
Therefore, the question of increased 
psychiatric and medical care of patients during 
pregnancy and postpartum is imposed. 
This study aimed to determine the influence of 
SSRI antidepressant therapy and psycho-social 
therapeutic interventions on depression during 
pregnancy. It was also our aim to define the relation 
between severity of depression and 
sociodemographic characteristics. 
 
 
Material and Methods 
 
The investigation comprised 40 women with 
dg. F32 or F33 according to ICD 10, that is depressive 
condition with expressed characteristics manifested 
during depressive episodes and recurrent depressive 
disorder. 
Patients were of different age, different 
environment, working status, education, and marital 
status. They were also tested for heredity presence. 
Patients were examined by using the scales 
for assessment of depression and anxiety, HAMD 
rating scale for the severity of depression, and HAMA 
rating scale for the severity of anxiety. In addition to 
these two scales, the clinically structured interview 
was used for obtaining data about pregnancy, 
heredity, previous treatment or use of antidepressant 
medications and other characteristics. 
Patients were treated with SSRI 
antidepressant therapy initiated in the 10-12 week 
with gradual reduction or discontinuation of 
medications by the end of the pregnancy, i.e., in the 
last 8 gestational weeks. 
They were evaluated at the beginning of the 
treatment and 3 months after antidepressant 
treatment. 
All patients were informed about the treatment 
and the risk/benefit ratio regarding their physic 
condition and pregnancy. All of them paid regular 
visits to a gynaecologist. The follow-up period was two 
years. 
Results 
 
Table 1 presents the sociodemographic 
characteristics of patients. The larger number of them 
was at the age over 30 years, with completed higher 
education, term delivery and without heredity 
inheritance.  
Table 1: Sociodemographic characteristics of patients 
Age Count Per cent 
< 30 10 24.4 
> = 30 29 70.7 
> = 40 2 4.9 
Pregnancy 
I 29 70.7 
II 8 19.6 
III 3 7.3 
IV 1 2.4 
Education 
Faculty 22 53.8 
Higher 16 39.0 
Basic 3 7.2 
Employees 
Yes 22 53.7 
No 19 46.3 
Delivery 
Time 34 82.9 
Caesarean section 4 9.8 
Before time 3 7.3 
Therapy 
With 4 9.8 
Without 37 90.2 
Heredity   
- 32 78.0 
+ 9 22.0 
 
They were treated with antidepressant 
medications and the largest number with sertraline 
and escitalopram. In a smaller number of patients, 
antipsychotic medications at small doses were added 
(up to 1 mg risperidone and up to 5 mg olanzapine) as 
adjuvant therapy (Table 2). 
Table 2: Therapy administered in patients 
Therapy Count Per cent 
Escitalopram 9 21.6 
Sertraline 15 36.6 
Without therapy 4 9.8 
Escitalopram, risperidone 3 7.3 
Sertraline, risperidone 5 12.2 
Escitalopram, risperidone, alprazolam 1 2.4 
Venlafaxine 1 2.4 
Citalopram 2 4.9 
Olanzapine, sertraline 1 2.4 
Total 41 100.0 
 
The average HAM anxiety score in patients 
on 0 days was 36.0 ± 5.2 (severe anxiety), and after 3 
months the score reduced to 22.2 ± 3.3 (moderate). 
The difference was 13.8 units. According to t-test the 
difference was statistically significant for p < 0.05 (p = 
0.00000) (Table 3 and Figure 1). 
 
Table 3: Average HAMA score, 0 days and after 3 months  
Hama 
Mea
n 
Std.dv
. 
N Diff. 
Std.dv. 
- diff. 
T Df P 
Confidenc
e - 95.0% 
Confidence 
+95.0% 
0 day 36.0 5.236 
        
After 
3m 
22.2 3.285 41 13.8 3.831 23.153 40 <0.001 12.644 15.062 
 
HAM severe anxiety disorder was registered 
in 71.0% (22) of patients older than 30 years, and in 
30.0% (3) younger than 30 years. 
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Figure 1: Average HAMA score, 0 days and after 3 months 
 
A statistically significant relation was 
registered between age (over and under 30 y.) and 
the HAM anxiety score for p < 0.05 (Pearson Chi-
square: 6.384, df = 2, p = 0.0410) (Table 3). 
HAM severe anxiety disorder was registered 
in 63.6% (14) of patients with an obtained university 
degree, in 62.5% (10) with completed high education 
and 33.3% (1) with primary education. No statistically 
significant relation was observed between education 
and HAM anxiety score for p < 0.05 (Pearson Chi-
square: 0.893, df = 2, p = 0.639) (Table 3). 
HAM severe anxiety disorder was registered 
in 100% (4) of patients who were delivered with a 
Cesarean section, in 100% [3] with preterm delivery 
and 52.9% (18) with term delivery.  
No statistically significant relation was 
registered between mode of delivery and HAM anxiety 
score for p<0.05 (Pearson Chi-square: 5.402, df=4, p= 
0.248) (Table 3).  
HAM severe anxiety disorder was registered 
in 56.3% (18) of patients who were with negative 
heredity, and in 77.8% (7) in those with positive 
heredity. 
No statistically significant relation was 
registered between heredity and HAM anxiety score 
for p < 0.05 (Pearson Chi-square: 1.704, df = 2, p = 
0.426) (Table 3). 
The average HAM depression score was 33.4 
± 3.5 (severe anxiety) on day 0, and after 3 months it 
decreased to 20.8 ± 2.1 (moderate). The difference 
was 12.6 units. According to t-test the difference was 
statistically significant for p < 0.05 (p = 0.00) (Table 4 
and Figure 2). 
HAM severe depression disorder was 
registered in 90.3% (28) of patients older than 30 
years and in 60.0% (6) younger than 30 years. 
A statistically significant relation was found 
between age (over and under 30 y.) and HAM 
depression score for p < 0.05 (Pearson Chi-square: 
4.910, df = 1, p = 0.0266) (Table 4). 
Table 4: Average HAMD score, 0 days and after 3 months 
Hamd Mean Std.dv. N Diff. 
Std.dv. - 
diff. 
T Df P 
Confidence 
- 95.0% 
Confidence 
+95.0% 
0 day 33.4 3.498 
     
  
  
After 
3m 
20.8 2.079 41 12.6 2.408 33.464 40 0.00 11.825 13.345 
 
HAM severe depression disorder was 
registered in 86.4% (19) of patients with a university 
degree, in 87.5% (14) of those with completed high 
education and 33.3% (1) of patients with primary 
education. 
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Figure 2: Average HAMD score, 0 days and after 3 months 
 
No statistically significant relation was found 
between level of education and HAM depression 
score for p < 0.05 (Pearson Chi-square: 5.631, df = 2, 
p = 0.059) (Table 5). 
HAM severe depression disorder was 
registered in 86.2% (25) of primipara patients and in 
75.0% (9) of multipara patients. 
No statistically significant relation was found 
between number of pregnancies and HAM depression 
score for p < 0.05 (Pearson Chi-square: 0.752, df = 1, 
p = 0.385) (Table 5). 
HAM severe depression disorder was 
registered in 100% (4) of patients delivered with a 
Cesarean section, in 100.0% (3) of those who gave 
preterm childbirth and in 79.4% (27) of patients with 
normal delivery. 
No statistically significant relation was found 
between mode of delivery and HAM depression score 
for p < 0.05 (Pearson Chi-square: 1.737, df = 2, p = 
0.419) (Table 5). 
HAM severe depression disorder was 
registered in 81.2% (26) of patients with negative 
heredity and in 88.8% (8) of patients who were found 
to have positive heredity. 
No statistically significant relation was found 
between heredity and HAM depression score for p < 
0.05 (Pearson Chi-square: 0.289, df = 1, p = 0.590) 
(Table 5). 
Table 5: Relation between HAMA and HAMD versus 
sociodemographic characteristics 
Characteristics/ Pearson Chi-square  HAMA HAMD 
Age P = 0.041080* P = 0.026698* 
Pregnancy P = 0.64087 P = 0.385549 
Education P = 0.639839 P = 0.059864 
Delivery P = 0.248447 P = 0.419394 
Heredity P = 0.426384 P = 0.590536 
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Discussion 
 
The results obtained have shown a significant 
improvement in patients about the reduction of 
depression and anxiety after a 3-month 
psychopharmacological treatment. A statistically 
significant relation was found between the severity of 
depression and anxiety, on the one hand, and age, on 
the other. Patients older than 30 years presented with 
more expressed anxiety and depression than the 
younger pregnant women. 
In general, the largest number of primipara 
patients with depression was at the age over 30 
years, which coincides with the trend of getting 
married after the age of 30/later in life/and raising a 
family, but it might also be due to the need of secure 
socioeconomic status. 
Although there were more severe depression 
and anxiety disorders in patients with a university 
degree in comparison with those with a lower level of 
education, the difference was not statistically 
significant. More severe depression manifested in 
mothers with completed higher education might be a 
result of their higher awareness and consciousness 
about their psychological disorders and the need of 
expert help. 
The results have shown that a larger number 
of pregnant patients treated with antidepressant 
therapy had a normal delivery with the subsequent 
normal/unremarkable condition in both, the mother 
and the newborn infant; only one woman had preterm 
childbirth, and one had a Cesarean section. 
More than 80% of mothers were treated with 
SSRI antidepressant therapy, and they had 
normal/uncomplicated pregnancy and delivery, which 
speaks in favour of the risk/benefit ratio of applying 
antidepressant therapy. 
The task of each therapist/medical expert is to 
make an individual assessment of the severity of 
depression during pregnancy, the assessment of the 
risk for the mother and the newborn infant regarding 
the eventual damage or benefit from antidepressant 
medications [1] [2] [6] [7]. 
Majority of studies point out the differences in 
psychiatric treatment applied in women with a higher 
socioeconomic status compared to those with a lower 
one. Indicators show that women with a higher 
socioeconomic status were more likely to see a 
psychiatrist for depression during pregnancy and were 
treated with SSRI antidepressant medications, 
whereas those with a lower socioeconomic status 
were more likely to visit their family/general physicians 
asking for help about their depression during 
pregnancy [2]. 
The results of one research conducted across 
several European countries with different 
socioeconomic status indicated that major depression 
during pregnancy and after delivery was observed in 
women living in countries with lower socioeconomic 
status. This leads to the conclusion that these women 
rarely consult a psychiatrist during pregnancy, which 
consequently results in a more severe postnatal 
depression or delayed treatment of postpartum 
depression. The research has demonstrated that 
patients who were treated with SSRI medications 
during pregnancy or patients who had not 
discontinued their previously started SSRI treatment 
were at a lower risk of onset or deterioration/ 
exacerbation of the condition in the postnatal period. It 
can be concluded that the optimum treatment with 
SSRI is indispensable in patients with the major 
depressive disorder [4]. 
Literature data show that depression during 
pregnancy is associated with poor care of the mother 
for her health during pregnancy, including rare visits to 
a doctor’s office, irregular use of medications, 
substance abuse, increased risk for preterm birth and 
low birth weight, and emotional developmental 
difficulties in the children whose mothers suffered 
from depression during pregnancy or postpartum [3]. 
It is considered that depression before and 
during pregnancy is one of the larger risks for 
development of postpartum depression, which has a 
negative effect on the mother/child relation as well as 
on adequate care for herself and the child [8]. 
National Institute for Health and Clinical 
Excellence in the United Kingdom (NICE) guidelines 
and American Psychiatric Association (APA) 
recommend CBT (cognitive behavioural therapy) and 
SSRI antidepressant therapy [9]. 
Literature suggests that SSRI treatment 
during pregnancy has no statistically increased risk of 
giving birth to a child with congenital anomalies than 
other women [5] [9] [10]. 
In conclusion, the optimal combined treatment 
of peripartum depression reduces the risk of 
postpartum depression, which is a prerequisite for 
normal emotional and behavioural development of the 
child.  
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